Descriptive table of CODEG22 score in the TCGA RNA-seq training cohort (N = 173)
| Parameter . | TCGA training cohort (N = 173) . | Low score subset (n = 87) . | High score subset (n = 86) . | P . | Test type . |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 81 (46.8) | 39 (44.8) | 42 (48.8) | .71 | Pearson’s χ2 test |
| Male | 92 (53.2) | 48 (55.2) | 44 (51.2) | ||
| Age, median (range) | 58 (18-88) | 54 (18-81) | 62.5 (21-88) | <.001 | Wilcoxon test |
| WBC, median (range) | 17 (0.4-297.4) | 13.6 (0.4-297.4) | 28.3 (0.7-171.9) | .13 | Wilcoxon test |
| Blast percentage, median (range) | 72 (30-100) | 73 (30-100) | 71.5 (30-98) | .28 | Wilcoxon test |
| Karyotype | |||||
| Abnormal karyotype | 95 (55.9) | 48 (55.8) | 47 (56) | .99 | Fisher’s exact test |
| Normal karyotype | 75 (44.1) | 38 (44.2) | 37 (44) | ||
| Molecular risk groups | |||||
| Favorable | 33 (19.4) | 27 (31.4) | 6 (7.14) | <.001 | Pearson’s χ2 test |
| Intermediate | 92 (54.1) | 45 (52.3) | 47 (56) | ||
| Poor | 45 (26.5) | 14 (16.3) | 31 (36.9) | ||
| Cytogenetic abnormalities | |||||
| Normal karyotype | 75 (44.1) | 38 (44.2) | 37 (44) | <.001 | Fisher’s exact test |
| t(15;17) | 16 (9.41) | 13 (15.1) | 3 (3.57) | ||
| t(8;21) | 7 (4.12) | 6 (6.98) | 1 (1.19) | ||
| Inv(16) | 10 (5.88) | 8 (9.3) | 2 (2.38) | ||
| Intermediate risk cytogenetics | 21 (12.4) | 8 (9.3) | 13 (15.5) | ||
| Complex cytogenetics | 22 (12.9) | 4 (4.65) | 18 (21.4) | ||
| Poor-risk cytogenetics | 19 (11.2) | 9 (10.5) | 10 (11.9) | ||
| CN-AML mutations | |||||
| NPM1 mt | 43 (57.3) | 22 (57.9) | 21 (56.8) | .99 | Pearson’s χ2 test |
| NPM1 wt | 32 (42.7) | 16 (42.1) | 16 (43.2) | ||
| FLT3-ITD− | 59 (78.7) | 29 (76.3) | 30 (81.1) | .78 | Fisher’s exact test |
| FLT3-ITD+ | 16 (21.3) | 9 (23.7) | 7 (18.9) | ||
| Events | |||||
| No relapse | 91 (52.6) | 48 (55.2) | 43 (50) | .6 | Pearson’s χ2 test |
| Relapse | 82 (47.4) | 39 (44.8) | 43 (50) | ||
| Survival parameters | |||||
| OS time (median), mo | 18.1 | 56.3 | 8 | <.001 | Log-rank test |
| EFS time (median), mo | 9.8 | 20.8 | 5.8 | <.001 | Log-rank test |
| Parameter . | TCGA training cohort (N = 173) . | Low score subset (n = 87) . | High score subset (n = 86) . | P . | Test type . |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 81 (46.8) | 39 (44.8) | 42 (48.8) | .71 | Pearson’s χ2 test |
| Male | 92 (53.2) | 48 (55.2) | 44 (51.2) | ||
| Age, median (range) | 58 (18-88) | 54 (18-81) | 62.5 (21-88) | <.001 | Wilcoxon test |
| WBC, median (range) | 17 (0.4-297.4) | 13.6 (0.4-297.4) | 28.3 (0.7-171.9) | .13 | Wilcoxon test |
| Blast percentage, median (range) | 72 (30-100) | 73 (30-100) | 71.5 (30-98) | .28 | Wilcoxon test |
| Karyotype | |||||
| Abnormal karyotype | 95 (55.9) | 48 (55.8) | 47 (56) | .99 | Fisher’s exact test |
| Normal karyotype | 75 (44.1) | 38 (44.2) | 37 (44) | ||
| Molecular risk groups | |||||
| Favorable | 33 (19.4) | 27 (31.4) | 6 (7.14) | <.001 | Pearson’s χ2 test |
| Intermediate | 92 (54.1) | 45 (52.3) | 47 (56) | ||
| Poor | 45 (26.5) | 14 (16.3) | 31 (36.9) | ||
| Cytogenetic abnormalities | |||||
| Normal karyotype | 75 (44.1) | 38 (44.2) | 37 (44) | <.001 | Fisher’s exact test |
| t(15;17) | 16 (9.41) | 13 (15.1) | 3 (3.57) | ||
| t(8;21) | 7 (4.12) | 6 (6.98) | 1 (1.19) | ||
| Inv(16) | 10 (5.88) | 8 (9.3) | 2 (2.38) | ||
| Intermediate risk cytogenetics | 21 (12.4) | 8 (9.3) | 13 (15.5) | ||
| Complex cytogenetics | 22 (12.9) | 4 (4.65) | 18 (21.4) | ||
| Poor-risk cytogenetics | 19 (11.2) | 9 (10.5) | 10 (11.9) | ||
| CN-AML mutations | |||||
| NPM1 mt | 43 (57.3) | 22 (57.9) | 21 (56.8) | .99 | Pearson’s χ2 test |
| NPM1 wt | 32 (42.7) | 16 (42.1) | 16 (43.2) | ||
| FLT3-ITD− | 59 (78.7) | 29 (76.3) | 30 (81.1) | .78 | Fisher’s exact test |
| FLT3-ITD+ | 16 (21.3) | 9 (23.7) | 7 (18.9) | ||
| Events | |||||
| No relapse | 91 (52.6) | 48 (55.2) | 43 (50) | .6 | Pearson’s χ2 test |
| Relapse | 82 (47.4) | 39 (44.8) | 43 (50) | ||
| Survival parameters | |||||
| OS time (median), mo | 18.1 | 56.3 | 8 | <.001 | Log-rank test |
| EFS time (median), mo | 9.8 | 20.8 | 5.8 | <.001 | Log-rank test |
Data are the number of patients (percentage of entire set or subset), unless otherwise noted.
mt, nutation; wt, wild-type.